Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash & Current Investments (2023 - 2025)

Beta Bionics' Cash & Current Investments history spans 3 years, with the latest figure at $31.7 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 69.42% year-over-year to $31.7 million; the TTM value through Dec 2025 reached $31.7 million, down 69.42%, while the annual FY2025 figure was $31.7 million, 69.42% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $31.7 million at Beta Bionics, down from $228.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $249.7 million in Q2 2025 and bottomed at $13.0 million in Q2 2024.
  • The 3-year median for Cash & Current Investments is $96.7 million (2023), against an average of $110.5 million.
  • The largest YoY upside for Cash & Current Investments was 1816.65% in 2025 against a maximum downside of 69.42% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $96.7 million in 2023, then increased by 7.06% to $103.6 million in 2024, then crashed by 69.42% to $31.7 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Cash & Current Investments are $31.7 million (Q4 2025), $228.7 million (Q3 2025), and $249.7 million (Q2 2025).